DOI: 10.4244/EIJV9I8A170

The coronary artery bypass graft SYNTAX Score: final five-year outcomes from the SYNTAX-LE MANS left main angiographic substudy

Vasim Farooq1, MBChB, MRCP; Chrysafios Girasis1, MD; Michael Magro1, MD; Yoshinobu Onuma1, MD; Marie-Angèle Morel2, BSc; Jung Ho Heo1, MD; Hector M. Garcia-Garcia2 , MD; Arie Pieter Kappetein3, MD, PhD; Marcel van den Brand2, MD; David R. Holmes4, MD; Michael Mack5, MD; Ted Feldman6, MD; Antonio Colombo7, MD; Elisabeth Ståhle8, MD; Stefan James8, MD; Didier Carrié9, MD; Gerard Fournial9, MD; Gerrit Anne van Es2, PhD; Keith D. Dawkins

We recently reported the coronary artery bypass graft (CABG) SYNTAX Score, an objective measure of anatomical complexity and revascularisation post coronary artery bypass graft (CABG) surgery1. At four-year follow-up, a non-significant trend towards more adverse clinical outcomes, including all-cause death, was reported in the higher CABG SYNTAX group (≥22)1. The final five-year outcomes of the SYNTAX trial have recently been reported2,3. We report the five-year outcomes of the CABG SYNTAX Score from the CABG arm of the SYNTAX-LE MANS left main angiographic substudy.

At five years, significantly greater all-cause death was seen in the high CABG SYNTAX Score group (≥22) compared to the low CABG SYNTAX Score group (<22) (14.5% vs. 9.1%, log rank p-value=0.012) (Figure 1). Similarly, significantly greater five-year all-cause death/cerebrovascular accident (CVA)/myocardial infarction (MI) (log rank p-value=0.025) and MACCE (major adverse cardiac and cerebrovascular events) (log rank p-value=0.050) were reported.

Figure 1. Outcomes (Kaplan-Meier curves) separated by the median of the CABG SYNTAX Score into low (0-21) (n=58) and high (≥22) (n=55) score groups. At 5 years, significantly greater all-cause mortality (left image), significantly greater all-cause death/CVA/MI (middle image) and MACCE (right image) were evident in the high CABG SYNTAX Score group compared to the low CABG SYNTAX Score group. Note the peak in MACCE at approximately 18 months secondary to patients undergoing scheduled coronary angiography, the findings of which triggered repeat revascularisation. Log rank p-values are shown.

Incomplete revascularisation (ICR) has recently been hypothesised and shown to be a surrogate marker of a greater burden and complexity of coronary disease, other vascular disease, and clinical comorbidity, in both CABG and PCI (percutaneous coronary intervention) treated patients4,5. Specifically, in the all-comers CABG and PCI arms of the SYNTAX trial, adverse long-term (four-year) clinical outcomes –including mortality, all-cause revascularisation, and MACCE– were shown to occur more frequently in patients who were incompletely revascularised.

The CABG SYNTAX Score and its PCI equivalent, the residual SYNTAX Score6, both provide objective measures of the complexity of the residual disease and level of revascularisation. These scores may aid in determining a level of “reasonable revascularisation” after undergoing surgical or percutaneous-based revascularisation7, and may have a long-term prognostic role in identifying high-risk patients undergoing CABG or PCI. Validation studies are awaited.


The authors would like to thank all the study centres and participants.


The SYNTAX trial was funded by Boston Scientific.

Conflict of interest statement

K. Dawkins is a full-time employee of, and holds stock in, Boston Scientific. M. Mack has served on the speakers bureau of Boston Scientific, Cordis and Medtronic. T. Feldman has served on the speakers bureau of Boston Scientific; has received grant support from Abbott, Atritech, Boston Scientific Corporation, Edwards, and Evalve; and has worked as a consultant for Abbott, Coherex, Intervalve, Square One, and WL Gore. M-A. Morel’s institution has received a research grant from Boston Scientific. M-A. Morel, H.M. Garcia-Garcia and G.A. van Es are employees of Cardialysis. The other authors have no conflicts of interest to declare.


Volume 9 Number 8
Dec 27, 2013
Volume 9 Number 8
View full issue

Key metrics

On the same subject

Reply to the letter to the editor

10.4244/EIJ-D-23-00985 Feb 19, 2024
Reply: The ROTA-CUT randomised trial: push the button harder
Sharma S et al

Research Correspondence

10.4244/EIJ-D-23-00743 Feb 19, 2024
Final report of the PROTEMBO C Trial: a prospective evaluation of a novel cerebral protection device during TAVI
Fezzi S et al


10.4244/EIJ-E-24-00003 Feb 19, 2024
Between Scylla and Charybdis in atrial functional mitral regurgitation
Denti P

Letter to the editor

10.4244/EIJ-D-23-00937 Feb 19, 2024
Letter: The ROTA-CUT randomised trial: push the button harder
Novelli L et al

Original Research

10.4244/EIJ-D-23-00819 Feb 19, 2024
Outcomes of transcatheter edge-to-edge repair for atrial functional mitral regurgitation
Tanaka T et al


10.4244/EIJ-E-23-00071 Feb 19, 2024
One-year outcomes with a new mitral edge-to-edge repair device: is mitral TEER about to conquer the world?
Praz F and Samim D
Trending articles


10.4244/EIJ-D-22-00776 Apr 3, 2023
Computed tomographic angiography in coronary artery disease
Serruys PW et al


10.4244/EIJ-E-22-00007 May 15, 2022
TAVI at 20: how a crazy idea led to a clinical revolution
Eltchaninoff H et al

Expert consensus

10.4244/EIJ-E-22-00018 Dec 4, 2023
Definitions and Standardized Endpoints for Treatment of Coronary Bifurcations
Lunardi M et al

State of the art

10.4244/EIJ-D-22-00969 Jun 19, 2023
Functional coronary angiography for the assessment of the epicardial vessels and the microcirculation
Faria D et al

Clinical research

10.4244/EIJ-D-22-00621 Feb 20, 2023
Long-term changes in coronary physiology after aortic valve replacement
Sabbah M et al

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

Impact factor: 6.2
2022 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2023)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved